Details of the Drug Metabolized by Drug-Metabolizing Enzyme (DME)

General Information of Drug (ID: DR1103)
Drug Name
RO-111163
Synonyms
Aurorix; GNF-PF-695; Manerix; Moclaime; Moclamide; Moclamine; Moclobemid; Moclobemida; Moclobemida [INN-Spanish]; Moclobemide (Ro 111163); Moclobemide [USAN:BAN:INN]; Moclobemide [USAN:INN:BAN]; Moclobemidum; Moclobemidum [INN-Latin]; Ro 11-1163; moclobemide; 4-Chlor-N-(2-morpholinoethyl)benzamid; 4-Chloro-N-(2-(4-morpholinyl)ethyl)benzamide; 4-Chloro-N-(2-morpholin-4-yl-ethyl)-benzamide; 4-chloro-N-(2-morpholinoethyl)benzamide; 4-chloro-N-[2-(morpholin-4-yl)ethyl]benzamide; 71320-77-9; p-Chloro-N-(2-morpholinoethyl)benzamide
Indication Hypersalivation [ICD11: DA04] Phase 3 [1]
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 268.74 Topological Polar Surface Area 41.6
Heavy Atom Count 18 Rotatable Bond Count 4
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 3
Cross-matching ID
PubChem CID
4235
PubChem SID
846440 ; 4062293 ; 5184042 ; 8068729 ; 8152641 ; 10533635 ; 11193610 ; 12013032 ; 14750467 ; 17396732 ; 17441560 ; 26719626 ; 29223337 ; 46386631 ; 46504667 ; 46515904 ; 47365299 ; 47810845 ; 49876116 ; 50086440 ; 50105006 ; 50105007 ; 56311511 ; 57309677 ; 57322203 ; 57863431 ; 61117370 ; 76136224 ; 90340853 ; 92308246 ; 92711700 ; 103292864 ; 104171398 ; 104305815 ; 107817388 ; 117456677 ; 118397494 ; 121361553 ; 121363082 ; 124658882 ; 124800028 ; 125312350 ; 125356616 ; 126592938 ; 126630605 ; 126657143 ; 126684844 ; 129798217 ; 131324504 ; 131333978
ChEBI ID
CHEBI:83531
CAS Number
71320-77-9
TTD Drug ID
D01ZSO
Formula
C13H17ClN2O2
Canonical SMILES
C1COCCN1CCNC(=O)C2=CC=C(C=C2)Cl
InChI
1S/C13H17ClN2O2/c14-12-3-1-11(2-4-12)13(17)15-5-6-16-7-9-18-10-8-16/h1-4H,5-10H2,(H,15,17)
InChIKey
YHXISWVBGDMDLQ-UHFFFAOYSA-N
The Metabolic Roadmap of This Drug
The Full List of Drug Metabolites (DM) of This Drug
DM Name DM ID PubChem ID Reaction DM Level REF
Moclobemide M1 DM005968
4235
Oxidation - C-oxidation 1 [5]
Moclobemide M3 DM005976 N. A. Oxidation - Aromatic hydroxylation 1 [5]
Moclobemide M5 DM005974
163052
Oxidation - N-oxidation 1 [5]
Moclobemide M9 DM005977
26009
Oxidation - Oxidationn deamination 1 [5]
Moclobemide M16 DM005969 N. A. Oxidation - Oxidationn 2 [5]
Moclobemide M2 DM005972 N. A. Multi-steps Reaction - Oxidationn; reduction 2 [5]
Moclobemide M6 DM005975 N. A. Oxidation - Oxidationn 2 [5]
Moclobemide M7 DM005973 N. A. Multi-steps Reaction - Oxidationn; reduction 2 [5]
Moclobemide M8 DM005970 N. A. Reduction - Reduction 3 [5]
Moclobemide M4 DM005971 N. A. Reduction - Reduction 4 [5]
The Full List of Metabolic Reaction (MR) of This Drug
MR ID Reactant Product MR Type DME REF
MR006427 RO-111163 Moclobemide M1 Oxidation - C-oxidation CYP2C19 ... [5]
MR006433 RO-111163 Moclobemide M5 Oxidation - N-oxidation CYP2C19 ... [5]
MR006435 RO-111163 Moclobemide M3 Oxidation - Aromatic hydroxylation CYP2C19 ... [5]
MR006436 RO-111163 Moclobemide M9 Oxidation - Oxidationn deamination CYP2C19 ... [5]
MR006428 Moclobemide M1 Moclobemide M16 Oxidation - Oxidationn Unclear [5]
MR006431 Moclobemide M1 Moclobemide M2 Multi-steps Reaction - Oxidationn; reduction Unclear [5]
MR006432 Moclobemide M1 Moclobemide M7 Multi-steps Reaction - Oxidationn; reduction Unclear [5]
MR006434 Moclobemide M5 Moclobemide M6 Oxidation - Oxidationn Unclear [5]
MR006429 Moclobemide M16 Moclobemide M8 Reduction - Reduction Unclear [5]
MR006430 Moclobemide M8 Moclobemide M4 Reduction - Reduction Unclear [5]
⏷ Show the Full List of 10 MR(s)
Drug-Metabolizing Enzyme(s) (DME) Metabolizing This Drug
DME Name DME Info Species Uniprot ID EC Number REF
Cytochrome P450 2C9 (CYP2C9) DME0019 Homo sapiens
CP2C9_HUMAN
1.14.14.1
[2]
Cytochrome P450 2D6 (CYP2D6) DME0009 Homo sapiens
CP2D6_HUMAN
1.14.14.1
[3]
Mephenytoin 4-hydroxylase (CYP2C19) DME0021 Homo sapiens
CP2CJ_HUMAN
1.14.14.1
[4]
References
1 ClinicalTrials.gov (NCT00534573) Benzamide Derivates as Treatment of Clozapine-induced Hypersalivation.
2 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
3 Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther. 1995 Jun;57(6):670-7.
4 Effect of omeprazole on the pharmacokinetics of moclobemide according to the genetic polymorphism of CYP2C19. Clin Pharmacol Ther. 2001 Apr;69(4):266-73.
5 Biotransformation of moclobemide in humans

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.